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Microarrays
Demystified
Scientists are continually searching for
new, better, and faster ways to determine
which chemicals found in the environment
cause adverse health effects, and how they
do so. At the same time, the development
of new drug therapies depends upon a
clearer understanding of how environmen-
tal agents cause genetic changes that lead
to disease. Since 1997, the NIEHS
Microarray Group has been using microar-
rays to analyze changing patterns of gene
expression across the entire genome, study-
ing thousands of affected genes at a time
and revolutionizing the way that toxicolog-
ic problems are investigated. Today,
microarray “chips” allow researchers to
complete within a day or so an experiment
that would once have taken months using
traditional assays focusing on just one gene
at a time. 
One goal of toxicogenomics is to use
gene expression as a highly sensitive and
informative marker for toxicity. Using
microarrays, researchers can quickly and
accurately screen for large numbers of gene
expression responses to toxic substances
(alone or in mixtures), determine if toxic
effects occur at low-dose exposures, high-
light vulnerable tissue or cell types, and
begin to extrapolate effects from one
species to another. Over time, researchers
hope to identify genes associated with the
development of environmentally caused
diseases, including immune dysfunction
and cancer, as well as pulmonary, liver,
and neurologic diseases.
The Equipment
To make the type of microarray chips used
by the NIEHS group, up to 20,000 com-
plementary DNAs (cDNAs) or oligo-
nucleotides are spotted onto a small glass
substrate using high-speed robotics and
mechanical contact-printing pens. To test
a particular toxicant, RNA from treated
and control samples is reverse-transcribed
into cDNAs while incorporating fluores-
cent tags. If a red fluorescent tag is used for
the treated sample, then a green fluores-
cent tag will be used for the control sample
(or vice versa). 
The two fluorescent-labeled cDNA
groups are combined onto a microarray
chip that contains spots of gene fragments
complementary to the labeled cDNAs. An
overnight hybridization step allows the
labeled cDNAs to find and bind to their
complementary gene fragments. Laser scan-
ners detect the red and/or green fluorescent
signals of the spotted gene fragments to
reveal the relative abundance of the treated
and control cDNAs, and hence the relative
abundance of the original RNA transcripts.
The resulting patterns of color form a gene
expression profile, or signature, that points
out a possible toxic condition. 
According to center director Richard
Paules, the first human “ToxChip” micro-
arrays created in the lab contained only the
genes believed to be critically involved in
toxicity—about 2,000 in all. By the year
2000, researchers were using larger chips
with 7,000 clones of rat DNA. “Our goal
was to continue to increase our coverage to
represent [a] whole genome on a chip,”
Paules explains. Now chips containing
20,000 elements are available for human,
mouse, and rat DNA. Paules says the
group has processed more than 12,000
chips since its inception.
The group’s laboratory sports a pha-
lanx of sophisticated, often custom-made
equipment for fabricating microarrays,
scanning the images they produce, and
analyzing and archiving the resulting data.
A high-speed robotic arrayer prints 96
chips at once, dipping a printer head with
32 pins into a 384-well plate, with each
well containing the genetic material that is
deposited onto the slide. “We adjusted
humidity and temperature controls and
introduced liquid-handling robotics to
make the spots consistent and uniform,”
explains microarray lab manager Jeff
Tucker, whose background is in biomed-
ical engineering. 
Though the group first used its own
custom-made chips exclusively, it now for
the most part uses chips made by Agilent
Technologies, based in Palo Alto, Calif-
ornia. Agilent’s 20,000-clone human chips
are precisely uniform with perfectly circular
spots, Tucker says, giving more gene cover-
age and higher-quality data overall. 
As the chips have become more
advanced, so has the technology necessary to
interpret the data they produce. Three laser
scanners collect images produced by the flu-
orescent dyes used to label RNA on the
microarrays. The newest scanner, produced
by Agilent Technologies, can scan 48 slides
in one carousel run with a time of 7 minutes
per slide. The Agilent scanner complements
another scanner, manufactured by Axon
Instruments of Union City, California,
which scans one slide in 15 minutes. (By
comparison, the lab’s original laser scanner
took two hours to scan one slide.) Once
scanned, the images are statistically analyzed
and combined with clone identification
information using commercial software. 
The Experts
Analyzing massive amounts of data and
converting them to useful information
requires professionals skilled in bioinfor-
matics, a multidisciplinary field that com-
bines biology, genetics, information science
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Connecting the dots. Since 1997, scientists in the NIEHS Microarray Group have processed more
than 12,000 microarray “chips” in the search for better knowledge of how environmental factors
affect gene expression.NCT Update
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and technology, statistics, and mathemat-
ics. “We use informatics to manage high-
output biological data, then analyze and
interpret it,” explains bioinformatics man-
ager Pierre Bushel, a molecular biologist
and informatics expert. 
Even before a microarray is produced,
Bushel’s staff creates a database cataloguing
all the genes that will be deposited onto
the chip, along with each gene’s precise
location within the 384-well plates. This
effort alone produces thousands of records
and several fields, all for just one microar-
ray. The next step is image processing of
each chip to generate pixel intensity and
ratio measurements of each spot and even-
tually to determine any significant gene
expression changes. 
“Once data are structured and managed
using a professional database, we verify data
reliability and consistency,” explains
Bushel. He and his staff also develop their
own custom computational programs, as
well as novel algorithms and statistical
methods for identifying patterns in gene
expression data. “Our challenge is to make
the data accessible and interpretable to sci-
entists,” he says. “We build web application
environments and database portals so that
scientists from any location, at any time of
day, can retrieve the data they need and
analyze it.” The daily interaction between
bioinformatics specialists and scientists “has
been very fruitful,” he adds. “We deal with
problems so complex that we need a team-
oriented approach.” 
Paules agrees. “We’re really a collabora-
tive program that is unique [within] the
NIEHS. Working together, we form a
coalition across multiple types of expertise,”
he says. That expertise includes veterinary
pathologists, toxicologists, biochemists, and
specialists in microarray technology, infor-
matics, proteomics, and pharmacokinetics.
The group also collaborates with pharma-
ceutical consortia, biotechnology groups,
academicians, and statisticians, as well as
government agencies such as the Food and
Drug Administration (including its
National Center for Toxicology Research)
and the Environmental Protection Agency.
One of the group’s original mandates,
besides establishing a state-of-the-art gene
expression analysis research program and
doing proof-of-concept toxicogenomics
studies, was to serve the NIEHS’s intra-
mural research program. In keeping with
that purpose, the Microarray Group has
collaborated so far on more than 100 intra-
mural research projects. It also collaborates
on National Toxicology Program projects
and conducts its own studies as part of the
institute-based National Center for
Toxicogenomics.
Taking On Toxicants
So far, most of the group’s experiments have
focused on hepatotoxicity. “We’ve adopted a
careful approach to look at several hepato-
toxicants that are well known in terms of
how they affect the liver,” Paules explains.
“Our goal is to identify adverse changes
early, before irreversible damage occurs,”
thereby improving treatment methodologies
and boosting chances for prevention of liver
disease. Microarray studies may one day help
scientists identify a person’s genetic predis-
position to developing liver disease. So far,
the group has evaluated approximately 10
different compounds designated as possible
liver toxicants by the National Toxicology
Program, as well as compounds that humans
may be exposed to specifically via drugs as
well as elsewhere in the environment.
One such project, headed by postdoc-
toral researcher Alexandra Heinloth, focuses
on the toxic effects of acetaminophen on
the liver. Known to cause liver failure in
excessive amounts, acetaminophen is the
active ingredient in widely used over-the-
counter pain relievers such as Tylenol. It also
shows up in many over-the-counter cold
remedies, as well as in some prescription
painkillers. Alcohol exacerbates and intensi-
fies the drug’s effect on the liver because it
induces the activity of one of the enzymes
that metabolizes acetaminophen into its
toxic metabolite, explains Heinloth’s col-
league, postdoctoral fellow Todd Auman.
Currently, the research team is using
differential gene expression profiling to
understand how acetaminophen damages
liver cells. Using microarrays, the team has
performed numerous experiments using
different dosing levels and durations,
which can determine whether liver damage
is permanent or temporary. Searching for
clues, the researchers study multiple doses
at multiple time points and look for
repeating patterns that might signal a
genetic change or identify a gene involved
in a metabolic pathway that had not been
noted before. 
Taking things a step further, the
researchers are now using microarrays to
find clues as to whether gene activity that
takes place is occurring at a functional level.
To do this, researchers scrutinize cellular
RNA changes, then test for different protein
or metabolite levels. 
The researchers are moving away from
cDNA arrays to oligonucleotide arrays,
which Auman says “are coming close to
more complete coverage of the genome.”
However, the greater number of genes that
are being analyzed produces more data to
sift through and interpret. “It makes the
work more challenging,” Auman admits.
“It’s great for discovery; it opens more
avenues to research. But at the same time,
it’s harder to determine the story that is
unfolding.” –Jennifer Medlin
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ne goal of toxicogenomics is to use gene expression as a highly
sensitive and informative marker for toxicity. Using microarrays,
researchers can quickly and accurately screen for large numbers of
gene expression responses to toxic substances, determine if toxic effects occur 
at low-dose exposures, highlight vulnerable tissue or cell types, begin to 
extrapolate effects from one species to another, and eventually identify genes
associated with the development of environmentally caused diseases.